Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Food Safety News5d
UK health officials investigating listeria outbreak that has killed 3
Health officials in the United Kingdom are investigating a fatal Listeria outbreak linked to desserts supplied to the ...
PCMag5d
HP Omen Transcend 32 OLED Review
HP's Omen Transcend 32 OLED is a true dual threat: an outstanding 4K gaming display, as well as an excellent pick for the ...